Aug 29, 2025
AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE
Aug 05, 2025
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
Jun 30, 2025
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
Jun 23, 2025
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
Jun 18, 2025
AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
Jun 13, 2025
AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY
Jun 02, 2025
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
May 30, 2025
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
May 16, 2025
AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
May 01, 2025
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
Apr 28, 2025
AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
Apr 11, 2025
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
Apr 03, 2025
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
Mar 13, 2025
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
Mar 08, 2025
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Mar 04, 2025
AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
Feb 07, 2025
AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
Jan 31, 2025
AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Jan 08, 2025
AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Nov 29, 2024
AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE